SCHEMBL5572529

SCHEMBL5572529

CC(=O)Oc1ccc(C(F)(F)F)cc1-c1ccsc1

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.53
TMIGD3 P0DMS9 2/20 0.50
ADORA2A P29274 2/20 0.50
KDM4E B2RXH2 1/20 0.50
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
HPGD P15428 1/20 0.50
CYP2C19 P33261 1/20 0.50
HSD17B10 Q99714 1/20 0.50
PTGDR2 Q9Y5Y4 8/20 0.43
IDH2 P48735 7/20 0.40
SLC6A9 P48067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27724207 0.81 BACE1 (0.79) BACE1ADORA2AKDM4EUSP2ALDH1A1
SCHEMBL4055219 0.80 TMIGD3 (0.53) BACE1TMIGD3ADORA2AKDM4EALDH1A1
SCHEMBL5431285 0.80 PTGDR2 (0.70) PTGDR2SLC6A9
SCHEMBL16875842 0.76 CFTR (0.55) KDM4EIDH2
SCHEMBL1094881 0.76 BACE1 (0.53) BACE1KDM4EUSP2ALDH1A1HPGD
SCHEMBL16875837 0.75 KDM4E (0.50) KDM4EUSP2ALDH1A1HPGDCYP2C19
SCHEMBL27703302 0.74 PELI1 (0.50) TMIGD3ADORA2AIDH2
SCHEMBL5572639 0.73 ALDH1A1 (0.49) BACE1KDM4EUSP2ALDH1A1HPGD
SCHEMBL24436827 0.72 KDM4E (0.62) BACE1KDM4EUSP2ALDH1A1HPGD
SCHEMBL4981997 0.72 KDM4E (0.62) BACE1KDM4EUSP2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799658-A2 MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES AstraZeneca AB (SE) 2007-06-27 EP disclosed
WO-2006037982-A2 MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES ASTRAZENECA AB (SE) 2006-04-13 WO disclosed